颗粒酶B PET/CT预测微卫星稳定胃癌化疗免疫治疗结局
该回顾性研究纳入145例接受化疗免疫治疗后的微卫星稳定(MSS)胃癌患者,行[68Ga]Ga-NOTA-GSI PET/CT显像。应答者SUVmax、sumSUVmax及TBR显著高于非应答者,SUVmax预测应答AUC为0.755(新辅助亚组0.882);SUVmax≥2.6独立预测更长PFS(中位14.0 vs 9.0个月,HR 0.673,P=0.016)。
要点
- MSS胃癌化疗免疫治疗后[68Ga]Ga-NOTA-GSI PET/CT应答者摄取更高。
- SUVmax预测应答AUC全组0.755,新辅助亚组0.882。
- SUVmax≥2.6独立预测更长PFS,中位14.0 vs 9.0个月。
核心结论
- [68Ga]Ga-NOTA-GSI PET/CT对MSS胃癌化疗免疫治疗疗效评估和结局预测有显著价值。
研究设计与样本
- 回顾性研究纳入145例MSS胃癌患者,在化疗免疫治疗2或3周期后行[68Ga]Ga-NOTA-GSI PET/CT。
- 测量SUVmax、SUVmean、GSI肿瘤体积(GSI-TV)、总病灶摄取(TLU)、肿瘤-肝比值(TLR)和肿瘤-血比值(TBR)。
- 采用ROC曲线、logistic回归和Cox比例风险模型分析短期疗效与PFS的关联。
主要发现
- 应答者[68Ga]Ga-NOTA-GSI摄取显著高于非应答者,包括SUVmax、sumSUVmax和TBR(均P<0.05),见于全组及各亚组。
- 体积参数(GSI-TV、TLU)在应答与非应答者间无显著差异。
- SUVmax是全组应答的可靠预测因子(AUC=0.755),新辅助亚组AUC=0.882。
- SUVmax≥2.6独立预测显著更长PFS(中位PFS 14.0 vs 9.0个月;HR 0.673;P=0.016)。
关键数值与推荐
- 短期疗效评估采用RECIST 1.1或肿瘤退缩分级评分。
- SUVmax预测应答:全组AUC=0.755,新辅助亚组AUC=0.882。
- SUVmax≥2.6为独立预后因素:中位PFS 14.0 vs 9.0个月,HR 0.673,P=0.016。
临床怎么用
- MSS胃癌患者化疗免疫治疗2–3周期后可行[68Ga]Ga-NOTA-GSI PET/CT,以SUVmax等参数辅助评估疗效和预后。
- SUVmax≥2.6提示PFS更长,可支持治疗决策参考。
- 亚组分析提示该显像在新辅助、姑息和辅助治疗中均有预测价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prognostic stratification for microsatellite stable (MSS) gastric cancer (GC) remains challenging. This study evaluated the predictive and prognostic value of [68Ga]Ga-NOTA-GSI PET/CT imaging in a large cohort of MSS GC patients receiving chemo-immunotherapy. METHODS: In this retrospective study, 145 patients with MSS GC underwent [68Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy. Measurements included SUVmax, SUVmean, GSI tumor volume (GSI-TV), total lesion uptake (TLU), tumor-liver ratio (TLR), and tumor-blood ratio (TBR). The study analyzed associations between short-term treatment response (RECIST 1.1 or tumor regression grade score) and progression-free survival (PFS) using receiver operating characteristic (ROC) curves, logistic regression, and Cox proportional hazards models. RESULTS: Responders exhibited significantly higher uptake of [68Ga]Ga-NOTA-GSI than non-responders, including SUVmax, sumSUVmax, and TBR (all P < 0.05) across all patients and various subgroups, while volumetric parameters (GSI-TV, TLU) showed no notable difference. SUVmax was a reliable predictor of response (AUC = 0.755 for all patients; AUC = 0.882 for the neoadjuvant subgroup). In survival analysis, an SUVmax ≥ 2.6 independently predicted significantly longer PFS (median PFS of 14.0 vs. 9.0 months; hazard ratio, 0.673; P = 0.016). CONCLUSION: The study highlighted the significant value of [68Ga]Ga-NOTA-GSI PET/CT in assessing the effectiveness of chemo-immunotherapy and predicting outcomes in MSS gastric cancer patients. Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
引用
- Liu Q, Yang Z, Zhang J, et al. Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers. Eur J Nucl Med Mol Imaging. 2026. PMID: 41540242. doi:10.1007/s00259-025-07734-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。